Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

Bristol-Myers downgraded on disappointing news on lunch cancer drug

 (Image source: glassdoor.com)

Bristol-Myers Squibb Co (NYSE:BMY) shares are falling in the early session of trading as a result of a downgrade by BMO Capital. The drug maker was downgraded from outperform to market perform as the price target was also lowered to $55 a share from the prior target level of $60 a share. BMO cited disappointing new data on Bristol-Myers’ lung cancer drug which was once a source of positive news for the drug maker.